| 07/26/2024 16:30 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees |
| 07/26/2024 16:30 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors |
| 07/25/2024 16:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator |
| 07/25/2024 16:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees |
| 07/25/2024 16:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors |
| 07/08/2024 15:30 |
StemRIM Announces Patent Registration in Japan for Stem Cell Gene Therapy for Dystrophic Epidermolysis Bullosa |
| 06/17/2024 15:00 |
Patent Registration (Australia) for the Use of Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction |
| 06/12/2024 15:00 |
Non-consolidated Financial Results for the Nine Months Ended April 30, 2024 [Japanese GAAP] |
| 05/08/2024 15:00 |
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders , and Reduction of Capital Stock (Capital Decrease) |
| 03/21/2024 15:30 |
StemRIM Announces Symposium on "Regeneration-Inducing Medicine" at the 23rd Congress of the Japanese Society for Regenerative Medicine |
| 03/15/2024 16:00 |
Presentation Materials for the Six Months Ended January 31, 2024 |
| 03/13/2024 15:30 |
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy |
| 03/13/2024 15:30 |
Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP] |
| 02/29/2024 16:00 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators |
| 02/15/2024 15:00 |
StemRIM Announces Patent Registration (Japan) for the Use of Redasemtide, as a Therapeutic Indication of Therapeutic Medication for Cartilage Disorder |
| 02/14/2024 15:30 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborators |
| 01/31/2024 16:00 |
StemRIM Announces Patent Registration (Russia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders |
| 12/28/2023 16:00 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborator |
| 12/13/2023 15:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborator |
| 12/13/2023 15:00 |
Non-consolidated Financial Results for the Three Months Ended October 31, 2023[Japanese GAAP] |
| 12/06/2023 17:35 |
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation |
| 12/04/2023 15:00 |
StemRIM Announces Conclusion of Agreement for the Initiation of a Phase2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy |
| 11/16/2023 11:00 |
[Delayed]StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock |
| 11/16/2023 11:00 |
[Delayed]StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023 |
| 10/27/2023 16:45 |
[Delayed]StemRIM Announces Change of Representative Directors |
| 09/28/2023 16:00 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employee and External collaborator |
| 09/28/2023 14:15 |
[Delayed]StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Executive Officers, Employees, and External Collaborators |
| 09/20/2023 11:00 |
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Employee |
| 09/20/2023 11:00 |
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Director |
| 09/19/2023 17:00 |
[Delayed]Presentation Material, Financial Results for the Fiscal Year Ended July 31, 2023 |
| 09/19/2023 10:30 |
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employee and External collaborator |
| 09/19/2023 10:30 |
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employee |
| 09/19/2023 10:30 |
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Director |
| 09/13/2023 15:30 |
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2023 [Japanese GAAP] |
| 09/06/2023 15:00 |
StemRIM Announces Patent Registration (US) for the Use of Redasemtide as an Additional Therapeutic Indication for Cardiomyopathy |
| 09/04/2023 15:00 |
StemRIM Announces Patent Registration (China) for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction |
| 07/31/2023 16:00 |
StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke (Japan) |
